Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
企業コードCDIO
会社名Cardio Diagnostics Holdings Inc
上場日Nov 23, 2021
最高経営責任者「CEO」Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
従業員数13
証券種類Ordinary Share
決算期末Nov 23
本社所在地311 W. Superior Street
都市CHICAGO
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号60645
電話番号18552269991
ウェブサイト
企業コードCDIO
上場日Nov 23, 2021
最高経営責任者「CEO」Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし